Literature DB >> 2026181

In vivo and in vitro phosphorylation studies of numatrin, a cell cycle regulated nuclear protein, in insulin-stimulated NIH 3T3 HIR cells.

N Feuerstein1, P A Randazzo.   

Abstract

Numatrin, a nuclear matrix protein has been implicated to be involved in mitogenesis of normal and malignant cells (Feuerstein and Mond, J. Biol. Chem. 262, 11389, 1987) and was later found to be identical to the nuclear phosphoprotein, B23. To study whether phosphorylation of numatrin is regulated by mitogenic stimulation, we examined the effect of phosphorylation of numatrin in the insulin-responsive cells, NIH 3T3 HIR. We found that an increase in phosphorylation of numatrin was associated with stimulation of the cells with insulin for 4 h and that the level of phosphorylation remained elevated after 8 h. By this time there was no increase in numatrin abundance as shown by Coom-massie blue stain and Western blot analysis. The induction in phosphorylation of numatrin could not be detected after 30 min stimulation with insulin, thus, indicating that the increase in phosphorylation of numatrin is not a rapid event. Analysis of the phosphopeptides by thin layer chromatography indicated four peptides that were phosphorylated in numatrin (one major and three minor). Stimulation with insulin was associated primarily with an increase in phosphorylation of the minor phosphopeptides. The phosphopeptide map of numatrin was identical after 4, 8, 17, 24, and 32 h stimulation with insulin, indicating that identical sites are phosphorylated at different phases of the cell cycle. In a search for the protein kinase which is involved in phosphorylation of numatrin we found that numatrin is a most prominent substrate for the cell cycle regulated cdc2 (p 34) kinase. However, the major phosphopeptides which were phosphorylated by this kinase did not comigrate with either of the phosphopeptides phosphorylated in insulin-stimulated intact cells. This may indicate that it is unlikely that cdc2 kinase may account for the mechanism(s) associated with phosphorylation of numatrin by insulin under physiological conditions.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2026181     DOI: 10.1016/0014-4827(91)90367-4

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  7 in total

Review 1.  Nucleophosmin and human cancer.

Authors:  Mi Jung Lim; Xin Wei Wang
Journal:  Cancer Detect Prev       Date:  2006-11-17

2.  B23 is a downstream target of polyamine-modulated CK2.

Authors:  Kathryn Lawson; Laura Larentowicz; Lisa Laury-Kleintop; Susan K Gilmour
Journal:  Mol Cell Biochem       Date:  2005-06       Impact factor: 3.396

3.  Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis.

Authors:  D Bischof; K Pulford; D Y Mason; S W Morris
Journal:  Mol Cell Biol       Date:  1997-04       Impact factor: 4.272

4.  NPM phosphorylation stimulates Cdk1, overrides G2/M checkpoint and increases leukemic blasts in mice.

Authors:  Wei Du; Yun Zhou; Suzette Pike; Qishen Pang
Journal:  Carcinogenesis       Date:  2009-11-23       Impact factor: 4.944

5.  The G1 phase Cdks regulate the centrosome cycle and mediate oncogene-dependent centrosome amplification.

Authors:  Mary K Harrison; Arsene M Adon; Harold I Saavedra
Journal:  Cell Div       Date:  2011-01-27       Impact factor: 5.130

6.  Pharmacological AMP kinase activators target the nucleolar organization and control cell proliferation.

Authors:  Mohamed Kodiha; Ali Salimi; Yi Meng Wang; Ursula Stochaj
Journal:  PLoS One       Date:  2014-01-30       Impact factor: 3.240

7.  Destabilization of nucleophosmin mRNA by the HuR/KSRP complex is required for muscle fibre formation.

Authors:  Anne Cammas; Brenda Janice Sanchez; Xian Jin Lian; Virginie Dormoy-Raclet; Kate van der Giessen; Isabel López de Silanes; Jennifer Ma; Carol Wilusz; John Richardson; Myriam Gorospe; Stefania Millevoi; Matteo Giovarelli; Roberto Gherzi; Sergio Di Marco; Imed-Eddine Gallouzi
Journal:  Nat Commun       Date:  2014-06-27       Impact factor: 14.919

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.